Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Fortvita Biologics (Singapore) Pte. Ltd. currently manages 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units, indicating a portfolio that has begun to diversify its points of contact within the patent office. This distribution suggests a range of technical claims or a strategy to mitigate the impact of any single examiner's specific tendencies.
The busiest examiner for the company is PATTERSON, SARAH COOPER, who is responsible for 2 busiest examiner pending office actions. This concentration means that while the portfolio is split among 2 distinct examiners, a larger portion of the active workload remains with a single individual. The remaining workload is handled by another examiner, providing variety in the examination experience across the 2 distinct art units involved.
Managing 3 pending office actions across 2 distinct art units requires the applicant to navigate multiple sets of examiner preferences within the Biotechnology & Pharmaceuticals sector. The active workload suggests that the company is pursuing multiple patent applications simultaneously. This level of activity reflects a robust engagement with the patent system compared to portfolios with only a single pending matter. Future filings may further expand this footprint beyond the current examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (67%) |
| Double-patenting only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PATTERSON, SARAH COOPER | 2 | 55.3% | +59.5% |
| KAUFMAN, CLAIRE M | 1 | 63.5% | +50.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246939 | ANTI-CLAUDIN18.2 AND CD3 BISPECIFIC ANTIBODY AND USE THEREOF | KAUFMAN, CLAIRE M | 21d |
| 17911922 | INTERLEUKIN-2 MUTANT AND USE THEREOF | PATTERSON, SARAH COOPER | — |
| 17911893 | INTERLEUKIN-2 MUTANT AND USE THEREOF | PATTERSON, SARAH COOPER | — |
| Art Unit | Apps |
|---|---|
| 1675 | 2 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246939 | ANTI-CLAUDIN18.2 AND CD3 BISPECIFIC ANTIBODY AND USE THEREOF | KAUFMAN, CLAIRE M | 1674 | §112Other | Non-Final OA | 21d | Pending | Mar 28, 2023 |
| 17911922 | INTERLEUKIN-2 MUTANT AND USE THEREOF | PATTERSON, SARAH COOPER | 1675 | §112 | Final Rejection | — | Pending | Sep 15, 2022 |
| 17911893 | INTERLEUKIN-2 MUTANT AND USE THEREOF | PATTERSON, SARAH COOPER | 1675 | DP | Final Rejection | — | Pending | Sep 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial